drug pricing

Even with major progress on insulin affordability, many people with diabetes struggle under the weight of a costly system.

Op-Ed: Health Equity Requires More Than Good Intentions: Why 340B Needs Transparency Before Expansion - Black women and families in underserved communities face some...

Expanding a program that allows profits to grow without transparency while  also delivering minimal benefit to patients at the point-of-sale risks worsening those challenges rather than solving them. #drug #oped

Providers warn that recent actions by pharmaceutical manufacturers restricting how and where discounted medications can be dispensed are threatening the program, forcing hospitals and clinics to make difficult choices and putting patient care at risk in urban, suburban, and rural communities. #healthcare #drug #pricing

The 340B program requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations at significantly reduced prices. #drugs

In a statement released this week, Joshua Justin Travis, executive director of the Center for Healthcare Innovation, criticized the “Most Favored Nation” (MFN) model under debate in Washington, D.C. #healthcare

It's time to correct the course on 340B in Illinois... #340B

Instead, we call for thoughtful, equitable solutions that support—not sacrifice—the pillars of health and economic well-being in underserved communities. #MFN

Affordability is certainly an important factor for patients but so is accessibility. #prescription